Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 6/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21735572 | 0.98 | JAK1 (0.38) | JAK1NAMPTJAK2TLR7TLR8 | |
| SCHEMBL21735570 | 0.91 | JAK1 (0.40) | JAK1JAK2TLR7TLR8 | |
| SCHEMBL21735575 | 0.90 | JAK1 (0.38) | JAK1JAK2TLR7TLR8 | |
| SCHEMBL23916891 | 0.88 | TLR7 (0.38) | JAK1NAMPTJAK2TLR7TLR8 | |
| SCHEMBL21735574 | 0.86 | JAK1 (0.36) | JAK1TLR7TLR8 | |
| SCHEMBL21724395 | 0.86 | NLRP3 (0.44) | JAK1NAMPTTLR7TLR8GRM2 | |
| SCHEMBL21735576 | 0.86 | NAMPT (0.37) | NAMPTTLR7TLR8 | |
| SCHEMBL23917055 | 0.86 | TLR7 (0.39) | NAMPTTLR7TLR8 | |
| SCHEMBL23916902 | 0.83 | JAK1 (0.40) | JAK1JAK2TLR7TLR8 | |
| SCHEMBL21735565 | 0.80 | TLR7 (0.35) | JAK1JAK2TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317118-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2021-10-14 | — | — | US | disclosed |
| WO-2020037092-A1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317118-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | JAK1 2951/4885NAMPT 122/4885JAK2 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.